Vericiguat for the treatment of heart failure with reduced ejection fraction

References

• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322 .
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cardiovascular Disease (CVDs) [WHO web site]. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/index.html. cited 2015 Sept 27
   Google Scholar
• Virani SS, Alonso A, Benjamin EJ, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–e596 .
   PubMed Web of Science ®Google Scholar
• Murphy SP, Ibrahim NE, Januzzi JL, et al. Heart Failure With Reduced Ejection Fraction. JAMA. 2020;324(5):488.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Vaduganathan M, Fonarow GC, et al. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61:391–403.
   PubMed Web of Science ®Google Scholar
• Greene SJ, Khan MS. Quadruple medical therapy for heart failure: medications working together to provide the best care. J Am Coll Cardiol. 2021 Mar 23;77(11):1408–1411. PMID: 33736822
   PubMed Web of Science ®Google Scholar
• Borovac JA. Early in-hospital initiation and optimization of comprehensive disease-modifying pharmacotherapy in patients with heart failure with reduced ejection fraction: a time for the paradigm shift. Expert Rev Cardiovasc Ther. 2022 Feb;20(2):91–94. Epub 2022 Feb 9. PMID: 35129038
   PubMedGoogle Scholar
• Butler J, Yang M, Manzi MA, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73:935–944.
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–e292.
   PubMed Web of Science ®Google Scholar
• FDA approves verquvo (vericiguat) for heart failure with reduced ejection fraction. https://www.goodrx.com/verquvo/fda-approves-verquvo-for-heart-failure. Published January 2021, cited Mar 7.
   Google Scholar
• Boettcher M, Gerisch M, Lobmeyer M, et al. Metabolism and pharmacokinetic drug-drug interaction profile of vericiguat, A soluble guanylate cyclase stimulator: results from preclinical and phase I healthy volunteer studies. Clin Pharmacokinet. 2020;59(11):1407–1418.
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information VERQUVO safely and effectively. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214377s000lbl.pdf. [cited 2023 Feb 12].
   Google Scholar
• Follmann M, Ackerstaff J, Redlich G, et al. Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure. J Med Chem. 2017;60(12):5146–5161.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Marti CN, Sabbah HN, et al. Academic Research Team in Heart Failure (ART-HF). Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev. 2013 Mar;18(2):123–134. PMID: 22622468
   PubMed Web of Science ®Google Scholar
• Mitrovic V, Hemandez AF, Meyer M, et al. Role of guanylate cyclase modulators in decompensated heart failure. Heart Fail Rev. 2009;14(4):309–319.
   PubMedGoogle Scholar
• Emdin M, Aimo A, Castiglione V, et al. Targeting cyclic guanosine monophosphate to treat heart failure: JACC review topic of the week. J Am Coll Cardiol. 2020;76(15):1795–1807.
   PubMed Web of Science ®Google Scholar
• Breitenstein S, Roessig L, Sandner P, et al. Novel sGC stimulators and sGC activators for the treatment of heart failure. Handb Exp Pharmacol. 2017;243:225–247.
   PubMedGoogle Scholar
• Mathar I, Pavkovic M, Scheerer N, et al. The sGC stimulator vericiguat improved outcome in a rodent model of heart fail- ure with preserved ejection fraction (HFpEF). Circulation. 2018;138:A15553.
   Web of Science ®Google Scholar
• Armstrong PW, Roessig L, Patel MJ, et al. A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safely of the oral soluble guanylate cyclase stimulator: the Victoria trial. JACC Heart Fail. 2018;6(2):96–104.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericigual, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure ard reduced. Jama. 2015;314(21):2251–2262.
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp. VERQUVO” (vericigual) tablets, for oral use: US prescribing information. 2021. https://dailymed.nim.mih.gov. cited 2022 Apr 20
   Google Scholar
• Boettcher M, Thomas D, Mueck W, et al. Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat; results from six phase I studies in healthy subjects. Eur J Clin Pharmacol. 2021;77:527–537.
   PubMed Web of Science ®Google Scholar
• Verquvo. Package insert. Merck sharp and dome corp. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/labcl/2021/214377s0001bl.pdf. cited 2021 May 10
   Google Scholar
• European Medicines Agency. VERQUVO* (vericigual): FU/ summary of product characteristics. 2021. https://www.ema.europaeu. cited 2022 Apr 20
   Google Scholar
• Pieske B, Butler J, Filippatos C, et al. Rationale and design of the SOluhle guanylate Cyclase stimulatoR in heArT’ failure Studies (SOCRATES). Fur Heurt Fail. 2014;16:1026–1038.
   PubMed Web of Science ®Google Scholar
• Boettcher M, Loewen S, Gerrits M, et al. Pharmacodynamic and pharmacokinetic interaction profile of vericiguat: results from three randomized phase i studies in healthy volunteers. Clin Pharmacokinet. 2021 Mar;60(3):337–351. PMID: 33030703; PMCID: PMC7932970
   PubMed Web of Science ®Google Scholar
• Boettcher M, Mikus G, Trenk D, et al. Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: the randomized, phase Ib, VISOR study. Clin Transl Sci. 2022 May;15(5):1204–1214. Epub 2022 Mar 17. PMID: 35299288; PMCID: PMC9099120
   PubMedGoogle Scholar
• Boettcher M, Düngen HD, Donath F, et al. Vericiguat in combination with short-acting nitroglycerin in patients with chronic coronary syndromes: the randomized, phase Ib, VENICE Study. Clin Pharmacol Ther. 2022 Jun;111(6):1239–1247. Epub 2022 Mar 28. PMID: 35258101; PMCID: PMC9310564
   PubMedGoogle Scholar
• Pieske B, Maggioni AP, Lam CSP, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017 Apr 14;38(15):1119–1127.
   PubMed Web of Science ®Google Scholar
• Armstrong PW, Lam CSP, Anstrom KJ, et al.; VITALITY-HFpEF Study Group. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. JAMA. 2020 Oct 20;324(15):1512–1521.
   PubMed Web of Science ®Google Scholar
• Armstrong PW, Pieske B, Anstrom KJ, et al.; VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020 May 14;382(20):1883–1893.
   PubMed Web of Science ®Google Scholar
• Senni M, Alemayehu WG, Sim D, et al.; VICTORIA Study Group. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the Victoria trial. Eur J Heart Fail. 2022 Sep;24(9):1614–1622.
   PubMed Web of Science ®Google Scholar
• Butler J, Stebbins A, Melenovský V, et al.; VICTORIA Study Group. Vericiguat and health-related quality of life in patients with heart failure with reduced ejection fraction: insights from the Victoria trial. Circ Heart Fail. 2022 Jun;15(6):e009337.
   PubMedGoogle Scholar
• Ponikowski P, Alemayehu W, Oto A, et al.; VICTORIA Study Group. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the Victoria trial. Eur J Heart Fail. 2021 Aug;23(8):1300–1312.
   PubMed Web of Science ®Google Scholar
• Voors AA, Mulder H, Reyes E, et al.; VICTORIA Study Group. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the Victoria (Vericiguat global study in subjects with HFrEF) trial. Eur J Heart Fail. 2021 Aug;23(8):1313–1321.
   PubMed Web of Science ®Google Scholar
• Lam CSP, Giczewska A, Sliwa K, et al.; VICTORIA Study Group. Clinical outcomes and response to vericiguat according to index heart failure event: insights from the Victoria trial. JAMA Cardiol. 2021 Jun 1;6(6):706–712.
   PubMed Web of Science ®Google Scholar
• Ezekowitz JA, Zheng Y, Cohen-Solal A, et al. Hemoglobin and clinical outcomes in the vericiguat global study in patients with heart failure and reduced ejection fraction (Victoria). Circulation. 2021 Nov 2;144(18):1489–1499.
   PubMedGoogle Scholar
• Ezekowitz JA, O’Connor CM, Troughton RW, et al. N-terminal Pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. JACC Heart Fail. 2020 Nov;8(11):931–939. Epub 2020 Oct 7. PMID: 33039447
   PubMed Web of Science ®Google Scholar
• Senni M, Lopez-Sendon J, Cohen-Solal A, et al. Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the Victoria trial. ESC Heart Fail. 2022 Jul 26. Epub ahead of print. PMID: 35880474. doi: 10.1002/ehf2.14050
   Google Scholar
• A study of Vericiguat (MK-1242) in participants with chronic heart failure with reduced ejection fraction (hfref) (MK-1242-035) - (no date) A study of vericiguat (MK-1242) in participants with chronic heart failure with reduced ejection fraction (HFrEF) (MK-1242-035) - Full text view - clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT05093933. [cited February 12, 2023].
   Google Scholar
• González-Juanatey JR, Anguita-Sánchez M, Bayes-Genís A, et al. Vericiguat in heart failure: from scientific evidence to clinical practice. Rev Clin Esp (Barc). 2022 Jun-Jul;222(6):359–369. Epub 2022 Apr 23. PMID: 35473692
   PubMed Web of Science ®Google Scholar
• Ficha técnica de vericiguat. Primera publicación. 2021. Available from: https://www.ema.europa.eu/en/documents/assessment-report/verquvo-epar-public-assessment-reporten.pdfhttps://ec.europa.eu/health/documents/community-register/2021/20210716152073/anx152073es.pdf
   Google Scholar
• Vyas A, Onteddu N. Vericiguat. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2022 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK574528/. [cited 2022 Sep 2]
   Google Scholar
• Khan MS, Khan MS, Moustafa A, et al. Efficacy and safety of mineralocorticoid receptor antagonists in patients with heart failure and chronic kidney disease. Am J Cardiol. 2020 Feb 15;125(4):643–650.
   PubMed Web of Science ®Google Scholar
• Hsiao FC, Lin CP, Yu CC, et al. Angiotensin receptor-neprilysin inhibitors in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease: a retrospective multi-institutional study. Front Cardiovasc Med. 2022 Mar 8;9:794707.
   PubMedGoogle Scholar
• Adamson C, Docherty KF, Heerspink HJL, et al. Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation. 2022 Aug 9;146(6):438–449.
   PubMedGoogle Scholar
• Campbell N, Kalabalik-Hoganson J, Frey K, et al. Vericiguat: a novel oral soluble guanylate cyclase stimulator for the treatment of heart failure. Ann Pharmacother. 2022 May;56(5):600–608. Epub 2021 Aug 25. PMID: 34431706.
   PubMed Web of Science ®Google Scholar
• Kotecha D, Gill SK, Flather MD, et al; Beta-Blockers in Heart Failure Collaborative Group. Impact of renal impairment on beta-blocker efficacy in patients with heart failure. J Am Coll Cardiol. 2019 Dec 10;74(23):2893–2904.
   PubMedGoogle Scholar
• Ema (2021) Verquvo, European Medicines Agency. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/verquvo [cited Feb 12, 2023).
   Google Scholar
• Khan MS, Xu H, Fonarow GC, et al. Applicability of vericiguat to patients hospitalized for heart failure in the United States. JACC Heart Fail. 2023;11(2): 211–223. DOI:10.1016/j.jchf.2022.11.007. Feburary 2023 .
   PubMedGoogle Scholar
• Delgado JF, Ferrero Gregori A, Fernández LM, et al. Patient-associated pre- dictors of 15- and 30-day readmission after hospitalization for acute heart failure. Curr Heart Fail Rep. 2019;16:304–314.
   PubMedGoogle Scholar
• Buddeke J, Bots ML, van Dis I, et al. Trends in comorbidity in patients hospitalised for cardiovascular disease. Int J Cardiol. 2017;248:382–388.
   PubMedGoogle Scholar
• Greene SJ, Mentz RJ, Felker GM, et al. Outpatient worsening heart failure as a target for therapy: a review. JAMA Cardiol. 2018;3:252–259.
   PubMedGoogle Scholar
• Butler J, Djatche LM, Lautsch D, et al. Representativeness of the Victoria trial population in clinical practice: analysis of the PINNACLE registry. J Card Fail. 2021 Dec;27(12):1374–1381. Epub 2021 Jul 13. PMID: 34271161
   PubMed Web of Science ®Google Scholar
• Butler J, Usman MS, Anstrom KJ, et al. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum. Eur J Heart Fail. 2022 Nov;24(11):2029–2036. Epub 2022 Nov 16. PMID: 36250238
   PubMedGoogle Scholar
• Kenny M, Clarke MM, Pogue KT. Overview of riociguat and its role in the treatment of pulmonary hypertension. J Pharm Pract. 2022 Jun;35(3):437–444. Epub 2020 Oct 21. PMID: 33084500; PMCID: PMC9161433
   PubMedGoogle Scholar
• Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330–340.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2018;379(12):1116–1125.
   Google Scholar
• Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319–329.
   PubMed Web of Science ®Google Scholar
• Tran BA, Serag-Bolos ES, Fernandez J, et al. Vericiguat: the first soluble guanylate cyclase stimulator for reduction of cardiovascular death and heart failure hospitalization in patients with heart failure reduced ejection fraction. J Pharm Pract. 2022 Mar 31;8971900221087096. doi: 10.1177/08971900221087096. Epub ahead of print. PMID: 35356844
   Google Scholar
• Alsumali A, Djatche LM, Briggs A, et al. Cost effectiveness of vericiguat for the treatment of chronic heart failure with reduced ejection fraction following a worsening heart failure event from a us medicare perspective. Pharmacoeconomics. 2021 Nov;39(11):1343–1354. Epub 2021 Oct 8. PMID: 34623625; PMCID: PMC8516766
   PubMedGoogle Scholar
• Alsumali A, Lautsch D, Liu R, et al. Budget impact analysis of vericiguat for the treatment of chronic heart failure with reduced ejection fraction following a worsening event. Adv Ther. 2021 May;38(5):2631–2643. Epub 2021 Apr 16. PMID: 33860924; PMCID: PMC8107071
   PubMedGoogle Scholar